Semax vs Selank: Mechanisms, Evidence & Differences

Semax and Selank are the two most-referenced nootropic research peptides, and they are frequently studied — and cited — side by side. They share a birthplace, a design trick, and a general research neighbourhood, yet they are distinct compounds with different sequences and different research questions attached to them. This article compares them for research identification and literature orientation only. It makes no claims about human use, safety, benefit, or how to administer anything.

Quick comparison

A shared Russian origin

Both peptides come out of the same research programme. Semax and Selank were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, which spent decades working on short regulatory peptides derived from naturally occurring human sequences. That common lineage is a large part of why the two names travel together in the literature and in supplier catalogues.

They also share a clever structural idea. Each was built by taking a short, biologically active parent sequence that the body degrades very quickly, and adding a C-terminal Pro-Gly-Pro extension to slow enzymatic breakdown. Native fragments like ACTH(4-10) and tuftsin are cleaved by peptidases within minutes, which limits how long they can act in a research model; the proline-rich tail is a well-worn way to blunt that degradation. Semax extends the ACTH(4-10) fragment; Selank extends the immune tetrapeptide tuftsin. The result in both cases is a more metabolically stable peptide than its parent — the same engineering move applied to two different starting points. Both are studied within the same neuropeptide-signalling research area, which groups short regulatory peptides examined for their effects on signalling pathways in laboratory neurobiology.

Distinct sequences, distinct research questions

Despite the shared blueprint, the two sequences are unrelated, and the research literature around each points in a different direction.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analogue of a fragment of adrenocorticotropic hormone. Importantly, the ACTH(4-10) region it is based on carries the fragment's reported neurotropic character without the hormonal domain that drives adrenal stimulation, so preclinical work does not describe it as a cortisol-releasing agent. Its most-studied readout is the BDNF system: in rodent models, Semax has been reported to raise brain-derived neurotrophic factor and to modulate its receptor TrkB in the hippocampus, and this is the mechanism most often invoked in cognition and neuroprotection studies.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) descends from tuftsin, a naturally occurring immunomodulatory peptide released from the Fc region of immunoglobulin G, and it retains a foot in that world. Its preclinical literature clusters around two themes. The first is anxiolytic-type behaviour in animal models, where reported effects have been compared with benzodiazepine reference compounds but without the sedation profile associated with that drug class. The second is immunomodulation, including effects on cytokine expression such as interleukin-6 and the balance of T-helper signals, which trace directly back to its tuftsin ancestry. Some rodent work also reports changes in BDNF expression and in GABAergic and serotonergic signalling, which is one reason its research context overlaps with Semax at the edges even though the two parent molecules are entirely different.

The evidence is preclinical

The important caveat for anyone reading this literature: most of the published Semax and Selank data come from animal and cell studies. Reports of BDNF elevation, TrkB modulation, and anxiolytic-type behaviour are observations in rodent and in-vitro models, not demonstrated outcomes in people, and they are not efficacy claims. Treat every mechanism described here as a research finding in a laboratory system.

• Semax has been reported to regulate BDNF and TrkB expression in the rat hippocampus, alongside behavioural changes in a learning task (Dolotov et al., Brain Research, 2006).
• Semax was reported to stimulate BDNF expression across several regions of the rat brain in vivo (Shadrina et al., 2003).
• Selank and GABA were shown to alter expression of genes involved in GABAergic neurotransmission in a human neuroblastoma cell line (Kolomin et al., Front Pharmacol, 2017).
• For the broader picture, browse the full literature on Semax and Selank on PubMed.

Why they are studied together

Three things pull Semax and Selank into the same conversation: a shared origin institute, the identical Pro-Gly-Pro stabilisation strategy, and an overlapping interest in neuropeptide signalling and BDNF as a research readout. That overlap in research context — not any established outcome — is why the pair is so often referenced side by side. This comparison does not recommend studying or combining them together, and nothing here should be read as evidence of efficacy for any purpose.

Handling and storage in Thailand

Do not infer a shared solvent, storage temperature, or shelf life from their similar research context. Use material-specific evidence or a validated protocol, with the reconstitution guide and Thailand storage guide as planning references. The Semax and Selank pages list current options and prices.